Goserelin ('Zoladex')-offering patients more choice in early breast cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/78094
Title:
Goserelin ('Zoladex')-offering patients more choice in early breast cancer.
Authors:
Mitchell, Helen
Abstract:
The luteinising hormone-releasing hormone analogue goserelin ('Zoladex') suppresses ovarian oestrogen production in pre- and perimenopausal women. Goserelin is a biodegradable, sustained-release 3.6 mg depot that is administered by subcutaneous injection every 28 days. Clinical trials in premenopausal women with hormone-sensitive early breast cancer have demonstrated that goserelin alone, or in combination with tamoxifen, is at least as effective as cyclophosphamide, methotrexate, 5-fluorouracil (CMF) chemotherapy. Goserelin plus tamoxifen after cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) chemotherapy resulted in improved disease-free survival compared with CAF alone. These trials have also shown that goserelin is well tolerated and is associated with less acute toxicity than cytotoxic chemotherapy. Early improvements in quality of life over the first 3-6 months of goserelin treatment support the use of this agent as an alternative to chemotherapy in this patient population. Patients should be provided with information on the benefits and risks associated with available treatment options so that they can be involved in the decision-making process.
Affiliation:
Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. helen.mitchell@christie-tr.nwest.nhs.uk
Citation:
Goserelin ('Zoladex')-offering patients more choice in early breast cancer. 2004, 8 Suppl 2:S95-103 Eur J Oncol Nurs
Journal:
European Journal of Oncology Nursing
Issue Date:
2004
URI:
http://hdl.handle.net/10541/78094
DOI:
10.1016/j.ejon.2004.09.004
PubMed ID:
15590321
Type:
Article
Language:
en
ISSN:
1462-3889
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorMitchell, Helen-
dc.date.accessioned2009-08-21T08:49:17Z-
dc.date.available2009-08-21T08:49:17Z-
dc.date.issued2004-
dc.identifier.citationGoserelin ('Zoladex')-offering patients more choice in early breast cancer. 2004, 8 Suppl 2:S95-103 Eur J Oncol Nursen
dc.identifier.issn1462-3889-
dc.identifier.pmid15590321-
dc.identifier.doi10.1016/j.ejon.2004.09.004-
dc.identifier.urihttp://hdl.handle.net/10541/78094-
dc.description.abstractThe luteinising hormone-releasing hormone analogue goserelin ('Zoladex') suppresses ovarian oestrogen production in pre- and perimenopausal women. Goserelin is a biodegradable, sustained-release 3.6 mg depot that is administered by subcutaneous injection every 28 days. Clinical trials in premenopausal women with hormone-sensitive early breast cancer have demonstrated that goserelin alone, or in combination with tamoxifen, is at least as effective as cyclophosphamide, methotrexate, 5-fluorouracil (CMF) chemotherapy. Goserelin plus tamoxifen after cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) chemotherapy resulted in improved disease-free survival compared with CAF alone. These trials have also shown that goserelin is well tolerated and is associated with less acute toxicity than cytotoxic chemotherapy. Early improvements in quality of life over the first 3-6 months of goserelin treatment support the use of this agent as an alternative to chemotherapy in this patient population. Patients should be provided with information on the benefits and risks associated with available treatment options so that they can be involved in the decision-making process.en
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectCancer Stagingen
dc.subject.meshAdult-
dc.subject.meshAntineoplastic Agents, Hormonal-
dc.subject.meshBreast Neoplasms-
dc.subject.meshChemotherapy, Adjuvant-
dc.subject.meshDelayed-Action Preparations-
dc.subject.meshDrug Administration Schedule-
dc.subject.meshFemale-
dc.subject.meshGoserelin-
dc.subject.meshGreat Britain-
dc.subject.meshHumans-
dc.subject.meshInjections, Subcutaneous-
dc.subject.meshMastectomy-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasm Staging-
dc.subject.meshPremenopause-
dc.subject.meshPrognosis-
dc.subject.meshRandomized Controlled Trials as Topic-
dc.subject.meshRisk Assessment-
dc.subject.meshSurvival Analysis-
dc.subject.meshTreatment Outcome-
dc.titleGoserelin ('Zoladex')-offering patients more choice in early breast cancer.en
dc.typeArticleen
dc.contributor.departmentChristie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. helen.mitchell@christie-tr.nwest.nhs.uken
dc.identifier.journalEuropean Journal of Oncology Nursingen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.